Inflammation is frequently associated with human benign prostatic hyperplasia (BPH) and may concur in the development of urinary obstruction.Cyclooxygenase-2 (COX-2) is an inducible pro-inflammatory enzyme. COX-2 is expressed in prostate tissue, including BPH, and it may stimulate prostate growth by its ability to increase prostaglandin synthesis, promote angiogenesis and inhibit apoptosis. The aim of the study was to analyze whether combination therapy with rofecoxib, a COX-2 inhibitor, and finasteride, an inhibitor of prostatic 5alfa-reductase, offers an advantage compared to finasteride monotherapy in patients with symptomatic BPH.

Finasteride and rofecoxib combination in the treatment of benign prostatic hyperplasia (BPH) / PROIETTI PANNUNZI, Laura; DI SILVERIO, Franco; Sciarra, Alessandro; Lolli, Francesca; TOSTI CROCE, Carlo; M., Poggi; Toscano, Vincenzo; S., Monti. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - STAMPA. - 28:(2005), p. 18. (Intervento presentato al convegno XXXI Congresso Nazionale della Società Italiana di Endocrinologia tenutosi a Genova nel 4-7 Maggio 2005).

Finasteride and rofecoxib combination in the treatment of benign prostatic hyperplasia (BPH)

PROIETTI PANNUNZI, LAURA;DI SILVERIO, Franco;SCIARRA, Alessandro;LOLLI, FRANCESCA;TOSTI CROCE, Carlo;TOSCANO, Vincenzo;
2005

Abstract

Inflammation is frequently associated with human benign prostatic hyperplasia (BPH) and may concur in the development of urinary obstruction.Cyclooxygenase-2 (COX-2) is an inducible pro-inflammatory enzyme. COX-2 is expressed in prostate tissue, including BPH, and it may stimulate prostate growth by its ability to increase prostaglandin synthesis, promote angiogenesis and inhibit apoptosis. The aim of the study was to analyze whether combination therapy with rofecoxib, a COX-2 inhibitor, and finasteride, an inhibitor of prostatic 5alfa-reductase, offers an advantage compared to finasteride monotherapy in patients with symptomatic BPH.
2005
XXXI Congresso Nazionale della Società Italiana di Endocrinologia
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Finasteride and rofecoxib combination in the treatment of benign prostatic hyperplasia (BPH) / PROIETTI PANNUNZI, Laura; DI SILVERIO, Franco; Sciarra, Alessandro; Lolli, Francesca; TOSTI CROCE, Carlo; M., Poggi; Toscano, Vincenzo; S., Monti. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - STAMPA. - 28:(2005), p. 18. (Intervento presentato al convegno XXXI Congresso Nazionale della Società Italiana di Endocrinologia tenutosi a Genova nel 4-7 Maggio 2005).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/192025
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact